With another GH/IGF-axis medicine
Safety flag
Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.
Interaction evidence source All research profiles
Blends
CJC-1295 / GHRP-2
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as CJC-1295 + GHRP-2
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
CJC-1295 / GHRP-2 is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
CJC-1295 / GHRP-2 is a fixed-ratio compounded blend of two different growth hormone secretagogues. CJC-1295, usually supplied in the blend without its albumin-binding DAC group, is a modified growth hormone-releasing hormone (GHRH) fragment that acts on pituitary GHRH receptors. GHRP-2, also called pralmorelin, is a synthetic hexapeptide agonist of the ghrelin receptor (GHS-R1a) that stimulates growth hormone release through a separate pathway and, like ghrelin, can also raise prolactin, ACTH, cortisol, and appetite. Pairing a GHRH analogue with a ghrelin mimetic is intended to exploit the additive GH response seen when both receptor systems are stimulated together.
Each component has been studied on its own in small human pharmacology settings. Pihoker and colleagues published phase I pharmacokinetic and pharmacodynamic data for GHRP-2 in 1998, Mericq and colleagues treated growth hormone-deficient children for eight months in the same year, and Laferrère and colleagues showed in 2005 that GHRP-2 increased food intake in healthy men. Arvat and colleagues documented its effects on prolactin, ACTH, and cortisol in 1997. Human data on CJC-1295 come from the with-DAC form in a 2006 program by Teichman and colleagues. No published clinical trial has evaluated the specific fixed-ratio CJC-1295 / GHRP-2 product, so combined efficacy and safety are untested.
The blend is not approved by the FDA, the EMA, or any comparable regulator, and neither ingredient is approved as a therapeutic in the United States; pralmorelin has been marketed in Japan only as a diagnostic agent for growth hormone deficiency. The FDA lists GHRP-2 among bulk substances that may present significant safety risks in compounding, citing immunogenicity, aggregation, peptide impurities, and reports of increased insulin requirements, infection, pancreatitis, and death. CJC-1295 salts were reviewed unfavourably by the FDA's compounding advisory committee in 2024. Both peptides appear by name on the World Anti-Doping Agency Prohibited List under section S2.
Compounded blends are typically supplied as a single lyophilised vial containing both peptides in a set mass ratio, reconstituted with bacteriostatic water for subcutaneous injection. Because the ratio is fixed by the compounder, an inventory record for a blend usually captures the total peptide mass per vial, the stated split between components, the lot number, and the reconstitution date rather than a single-compound concentration. No approved label governs storage or beyond-use dating, and stability of two peptides sharing one solution has not been characterised in published work; the compounding pharmacy's documentation is the only formal reference for handling.
- Category
- Blends
- Routes represented
- Subcutaneous (SubQ)
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
Safety evidence
Serious or important: peptide immunogenicity, aggregation, or impurity concerns.
Route-specific human safety and long-term adverse effects are not established.
Safety evidence sourceInteraction evidence
These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
Common questions
What is in a CJC-1295 GHRP-2 blend?
The blend combines two peptides in one vial: a modified GHRH(1-29) fragment marketed as CJC-1295, most often the short-acting form without DAC, and GHRP-2 (pralmorelin), a six-amino-acid ghrelin-receptor agonist. The first acts on GHRH receptors and the second on GHS-R1a receptors in the pituitary and hypothalamus. Compounders sell the pair in a fixed mass ratio, which differs between suppliers and has not been standardised by any regulator.
Is CJC-1295 GHRP-2 FDA approved?
No. The blend is a compounded product with no marketing approval anywhere. GHRP-2 is named on the FDA's list of bulk drug substances that may present significant safety risks, and the agency proposed in 2024 that CJC-1295 not be added to the section 503A bulks list. In Japan pralmorelin has been available as a diagnostic test agent for growth hormone deficiency, not as a treatment, which is the only regulatory approval for either component.
Does GHRP-2 raise cortisol and appetite?
Human studies indicate it can. Arvat and colleagues in 1997 recorded increases in prolactin, ACTH, and cortisol alongside the growth hormone response to GHRP-2, and Laferrère and colleagues in 2005 reported increased food intake in healthy men, consistent with its action as a ghrelin mimetic. These effects distinguish GHRP-2 from more selective agonists such as ipamorelin, which produced little cortisol or prolactin change in early studies.
Are CJC-1295 and GHRP-2 banned by WADA?
Yes. The World Anti-Doping Agency Prohibited List names CJC-1295 as an example of a GHRH analogue and GHRP-2 (pralmorelin) as an example of a growth hormone-releasing peptide, both under section S2.2.4, growth hormone-releasing factors. Substances in this class are prohibited at all times and are treated as non-specified substances. WADA has also published laboratory guidance for detecting growth hormone-releasing factors in urine.
Further reading
- Pihoker et al., J Clin Endocrinol Metab 1998 (GHRP-2 phase I pharmacokinetics and pharmacodynamics in children)
- Mericq et al., J Clin Endocrinol Metab 1998 (eight months of GHRP-2 in GH-deficient children)
- Laferrère et al., J Clin Endocrinol Metab 2005 (GHRP-2 increases food intake in healthy men)
- Arvat et al., Peptides 1997 (GHRP-2 and hexarelin effects on GH, prolactin, ACTH, and cortisol)
- Teichman et al., J Clin Endocrinol Metab 2006 (CJC-1295 pharmacokinetics in healthy adults)
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
- World Anti-Doping Agency, The Prohibited List (section S2.2)
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.